Clinical trials: Hand-foot Syndrome
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer
- Trial name
- NCT00245050
- Testing
- pyridoxine hydrochloride, doxorubicin HCL liposome
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Ovarian Neoplasms
Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)
The purpose of this study is to evaluate the safety and tolerability of Caelyx in women with advanced ovarian cancer, focusing on infusion reactions and palmar-plantar erythrodysesthesia.
- Trial name
- NCT00743431
- Testing
- Caelyx (Pegylated Lyposomal Doxorubicin)
- Volunteers
- 224 people
- Sponsor
- Merck Sharp & Dohme LLC
Hand and Foot Syndrome
Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy
Capecitabine (Xeloda) a drug in cancer therapy. Its use is limited often by its toxicities. This study is asking if vitamin B6 can prevent one of the common toxicities of xeloda which is numbness and/or rash of the hands and…
- Trial name
- NCT00767689
- Testing
- Vitamin B 6
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Cook County Health